Emily Jarvie's profile photo

Emily Jarvie

Toronto

Financial Journalist at Proactive Investors

Financial journalist @proactive_ca @proactive_NA 💸

Articles

  • Oct 3, 2023 | proactiveinvestors.com | Andrew Kessel |Emily Jarvie

    About Andrew Kessel Andrew is a financial journalist with experience covering public companies in a wide breadth of industries, including tech, medicine, cryptocurrency, mining and retail. In addition to Proactive, he has been published in a Financial Times-owned newsletter covering broker-dealer firms and in the Columbia Misourian newspaper as the lead reporter focused on higher education. He got his start with an internship at Rolling Stone magazine.

  • Sep 12, 2023 | proactiveinvestors.com | Andrew Kessel |Emily Jarvie

    About Andrew Kessel Andrew is a financial journalist with experience covering public companies in a wide breadth of industries, including tech, medicine, cryptocurrency, mining and retail. In addition to Proactive, he has been published in a Financial Times-owned newsletter covering broker-dealer firms and in the Columbia Misourian newspaper as the lead reporter focused on higher education. He got his start with an internship at Rolling Stone magazine.

  • Sep 12, 2023 | proactiveinvestors.com | Andrew Kessel |Emily Jarvie

    About Andrew Kessel Andrew is a financial journalist with experience covering public companies in a wide breadth of industries, including tech, medicine, cryptocurrency, mining and retail. In addition to Proactive, he has been published in a Financial Times-owned newsletter covering broker-dealer firms and in the Columbia Misourian newspaper as the lead reporter focused on higher education. He got his start with an internship at Rolling Stone magazine.

  • Sep 11, 2023 | proactiveinvestors.com | Emily Jarvie

    BioVie Inc (NASDAQ:BIVI) has unveiled early data from the Phase 3 study of its investigational drug NE3107 in patients with mild to moderate Alzheimer’s Disease, highlighting the preliminary baseline metabolic and inflammation characteristics of the study population. The update sent its shares higher, up 14% at US$3.92 late morning on Monday.

  • Aug 27, 2023 | proactiveinvestors.com | Stephen Gunnion |Emily Jarvie

    US stocks were higher in noon trading as investors brace for key inflation and employment data to be released later this week.   At midday, the Dow rose 183 points to 34,530 while the S&P 500 added 15 points at 4,421 and the tech-heavy Nasdaq gained 50 points to 13,641. “Today is much more of a cyclical lift versus tech, and I think that’s just from stronger-than-expected growth outside of the US,” Certuity co-chief investment officer Dylan Kremer said.

Contact details

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

X (formerly Twitter)

Followers
1K
Tweets
2K
DMs Open
Yes
Emily Jarvie
Emily Jarvie @emilyjjarvie
28 Feb 25

$IMUX Biotechs challenge big pharma with new oral weight loss therapies https://t.co/TLGZ7zM3lP @ImmunicInc #IMUX

Emily Jarvie
Emily Jarvie @emilyjjarvie
7 Feb 25

Could the Super Bowl decide the stock market’s next move? History says maybe https://t.co/bHNydSRVUq

Emily Jarvie
Emily Jarvie @emilyjjarvie
21 Nov 24

RT @ErasTourResell: SURPRISE!!!! We are doing a giveaway for a pair of tickets for the show in Toronto TOMORROW 11/22! Like, Repost, & a fr…